Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Cash & Equivalents over the past 12 years, most recently at $212.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $212.4 million for Q4 2025, up 113.25% from a year ago — trailing twelve months through Dec 2025 was $212.4 million (up 113.25% YoY), and the annual figure for FY2025 was $212.4 million, up 113.25%.
  • Cash & Equivalents for Q4 2025 was $212.4 million at Viridian Therapeutics, Inc.\DE, up from $169.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VRDN hit a ceiling of $344.2 million in Q3 2022 and a floor of $27.7 million in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $105.2 million (2023), compared with a mean of $116.1 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 361.7% in 2021 and later crashed 67.58% in 2023.
  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents stood at $42.3 million in 2021, then soared by 267.81% to $155.6 million in 2022, then tumbled by 33.91% to $102.8 million in 2023, then dropped by 3.14% to $99.6 million in 2024, then soared by 113.25% to $212.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $212.4 million (Q4 2025), $169.6 million (Q3 2025), and $117.3 million (Q2 2025) per Business Quant data.